http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 16:15:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+27/26990098.html si-local-file:///var/storage/secattach/20260827/26990098.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+27/26990098.html Thu, 27 Aug 2026 16:15:00 -0400 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+27/26990098.html si-local-file:///var/storage/secattach/20260827/26990098.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+27/26990098.html Thu, 27 Aug 2026 16:15:00 -0400 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+13/26918357.html si-local-file:///var/storage/secattach/20260813/26918357.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+13/26918357.html Thu, 13 Aug 2026 10:56:00 -0400 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+13/26918357.html si-local-file:///var/storage/secattach/20260813/26918357.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+13/26918357.html Thu, 13 Aug 2026 10:56:00 -0400 NRSN O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html <p>NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.</p> <p>The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.</p> <p>In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html Thu, 13 Aug 2026 09:31:20 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html <p>NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.</p> <p>The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.</p> <p>In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html Thu, 13 Aug 2026 09:31:20 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html <p>NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.</p> <p>The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.</p> <p>In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html Thu, 13 Aug 2026 09:31:20 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html <p>NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.</p> <p>The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.</p> <p>In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html Thu, 13 Aug 2026 09:31:20 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html <p>NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.</p> <p>The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.</p> <p>In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html Thu, 13 Aug 2026 09:31:20 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html <p>NeuroSense Therapeutics (NASDAQ: NRSN) disclosed in a shareholder letter that securing financing for its Phase 3 PARAGON study of PrimeC in amyotrophic lateral sclerosis (ALS) has taken longer than anticipated, while the company also faces Nasdaq listing deficiencies.</p> <p>The FDA has cleared NeuroSense to initiate PARAGON, which is expected to enroll approximately 300 participants, primarily in the United States. The company said it is pursuing financing through discussions with pharmaceutical companies, strategic partners, investors, grants, and other non-dilutive funding sources.</p> <p>In April 2026, CEO Alon Ben-Noon and CFO Or Eisenberg each invested $200,000 in the company. Combined with a contribution from an http://www.streetinsider.com/Corporate+News/NeuroSense+faces+funding+delays+for+Phase+3+ALS+trial%2C+Nasdaq+issues/26917766.html Thu, 13 Aug 2026 09:31:20 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/Press+Releases/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>Aug. 13, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today releases a letter from the CEO, <person>Alon Ben-Noon</person>, to investors.</p> <p> </p><div id="prni_dvprnejpgf77bleft" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpgf77bleft" title="NeuroSense Therapeutics Logo" src="https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg" alt="NeuroSense Therapeutics Logo" align="middle" /></div><p> </p><p><b>Dear Fellow Shareholders,</b></p><p>I wanted to take this opportunity to update you on NeuroSense's  preparations for the Phase 3 PARAGON study, our efforts to secure the resources needed to advance it, the regulatory opportunities we are pursuing in http://www.streetinsider.com/PRNewswire/NeuroSense+Issues+CEO+Letter+to+Shareholders/26917765.html Thu, 13 Aug 2026 09:30:00 -0400 A.06822034 A.17150087 NRSN O.20026344 O.31364977 O.34929518 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+06/26881889.html si-local-file:///var/storage/secattach/20260806/26881889.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+06/26881889.html Thu, 06 Aug 2026 11:56:00 -0400 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+06/26881889.html si-local-file:///var/storage/secattach/20260806/26881889.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Aug+06/26881889.html Thu, 06 Aug 2026 11:56:00 -0400 NRSN O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+targets+December+2026+Health+Canada+filing+for+ALS+drug/26881782.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) said it is targeting December 2026 for the filing of a New Drug Submission (NDS) with Health Canada for PrimeC, its ALS drug candidate, following the completion of the Pre-NDS process with the Canadian regulator.</p><p>Health Canada indicated it has no concerns with the company's proposed filing timeline and advised targeting early December, according to a press release from NeuroSense. The finalized meeting minutes reflect alignment between the two parties on the planned content and structure of the submission.</p><p>An NDS is the Canadian equivalent of a New Drug Application in the United States. Following administrative screening, http://www.streetinsider.com/Corporate+News/NeuroSense+targets+December+2026+Health+Canada+filing+for+ALS+drug/26881782.html Thu, 06 Aug 2026 11:34:57 -0400 NRSN